Facilitators and barriers affecting the implementation of e-health for chronic respiratory diseases in remote settings: a qualitative evidence synthesis.
Salmi EM. et al, (2025), BMC Health Serv Res, 25
FujiLAM for the diagnosis of childhood tuberculosis: a systematic review.
Olbrich L. et al, (2022), BMJ Paediatr Open, 6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Functional Asplenia and Specific Polysaccharide Antibody Deficiency in a Girl with SAVI.
Bijker EM. et al, (2021), J Clin Immunol, 41, 495 - 497
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR. et al, (2021), Nat Med, 27, 279 - 288
Publisher Correction: A guide to vaccinology: from basic principles to new developments.
Pollard AJ. and Bijker EM., (2021), Nat Rev Immunol, 21
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer KJ. et al, (2021), Nat Med, 27, 270 - 278
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M. et al, (2021), Lancet, 397, 99 - 111
A guide to vaccinology: from basic principles to new developments.
Pollard AJ. and Bijker EM., (2020), Nat Rev Immunol
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM. et al, (2020), Lancet, 396, 467 - 478